Clinical Trial Update: NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy for patients with advanced cancers; the study is currently act…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Cervical Cancer
• Head and Neck Squamous Cell Carcinoma
• Melanoma
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma
• Solid Tumor with Microsatellite Instability-high Status
• Triple-negative Breast Cancer

Drugs mentioned

• Anti-PD-1 Monoclonal Antibody
• NBTXR3 (hafnium oxide nanoparticles)

Snippet

Sponsor: Nanobiotix | Conditions: Radiotherapy, Immunotherapy | Phase 1 | Status: ACTIVE_NOT_RECRUITING